NEWS
Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial
Sight Sciences (Nasdaq: SGHT) announced the publication of a new study in Clinical Ophthalmology, demonstrating the efficacy of TearCaretreatment for dry eye disease (DED). The study, titled 'Impact of TearCare on Reading Speed in Patients with Dry Eye Disease,' revealed significant improvements in various metrics:
- 52% of participants showed clinically significant improvement in reading speed
- Statistically significant improvements in IReST and MNREAD scores
- Significant enhancements in OSDI and NEI-VFQ-25 scores, measuring symptoms and vision-related quality of life
- Significant improvements in all DED sign metrics
The prospective single-center study suggests that a single TearCaretreatment can improve vision-related quality of life and reading speeds in patients with meibomian gland disease associated DED. The findings indicate that this interventional approach should be considered to reduce the disease burden of MGD associated DED.
- 52% of participants showed clinically significant improvement in reading speed
- Statistically significant improvements in IReST and MNREAD scores
- Significant enhancements in OSDI and NEI-VFQ-25 scores, measuring symptoms and vision-related quality of life
- Significant improvements in all DED sign metrics
The prospective single-center study suggests that a single TearCaretreatment can improve vision-related quality of life and reading speeds in patients with meibomian gland disease associated DED. The findings indicate that this interventional approach should be considered to reduce the disease burden of MGD associated DED.
免責事項：このコミュニティは、Moomoo Technologies Inc.が教育目的でのみ提供するものです。
さらに詳しい情報
コメント
サインインコメントをする
Spread kindness and love. Life is short. Don’t let greed eat you.
2541フォロワー
107フォロー中
28K訪問者
フォロー